

# IDO - Immunologie humaine, pathophysiologie et immunothérapies

Rapport Hcéres

► **To cite this version:**

Rapport d'évaluation d'une entité de recherche. IDO - Immunologie humaine, pathophysiologie et immunothérapies. 2018, Université Paris Diderot - Paris 7, Institut national de la santé et de la recherche médicale - INSERM. hceres-02031451

**HAL Id: hceres-02031451**

**<https://hal-hceres.archives-ouvertes.fr/hceres-02031451>**

Submitted on 20 Feb 2019

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

REPORT ON THE RESEARCH UNIT:  
Human Immunology, Pathophysiology &  
Immunotherapy (HIPI)

UNDER THE SUPERVISION OF THE  
FOLLOWING INSTITUTIONS AND  
RESEARCH BODIES:

Université Paris Diderot  
Institut National de la Santé et de la Recherche  
Médicale - INSERM

**ÉVALUATION CAMPAIGN 2017-2018**  
GROUP D



In the name of Hcéres<sup>1</sup>:

Michel Cosnard, President

In the name of the expert committee<sup>2</sup>:

Salem Chouaib, Chairman of the  
committee

Under the decree No.2014-1365 dated 14 November 2014,

<sup>1</sup> The president of Hcéres "countersigns the evaluation reports set up by the expert committees and signed by their chairman." (Article 8, paragraph 5);

<sup>2</sup> The evaluation reports "are signed by the chairman of the expert committee". (Article 11, paragraph 2).

This report is the sole result of the unit's evaluation by the expert committee, the composition of which is specified below. The assessments contained herein are the expression of an independent and collegial reviewing by the committee.

## UNIT PRESENTATION

<b>Unit name:</b>	Human Immunology, Pathophysiology & Immunotherapy
<b>Unit acronym:</b>	HIPI
<b>Requested label:</b>	
<b>Application type:</b>	Restructuration
<b>Current number:</b>	
<b>Head of the unit (2017-2018):</b>	Mr Armand BENSUSSAN
<b>Project leader (2019-2023):</b>	Mr Armand BENSUSSAN & Mr Vassili SOUMELIS
<b>Number of teams:</b>	10

## COMMITTEE MEMBERS

<b>Chair:</b>	Mr Salem CHOUAIB, IGR, Villejuif
<b>Experts:</b>	Ms Myriam BOYER, IGMM, Montpellier (supporting personnel) Mr Jacques COLINGE, IRCM, Montpellier Ms Julie DECHANET-MERVILLE, Université de Bordeaux Mr John DE Vos, IRBM, Montpellier Ms Myriam LABALETTE, CHU Lille (representative of CNU) Mr Andrzej MACKIEWICZ, Poznan University of Medical Science, Poland Mr Tony NG, King's College, London, UK Ms Virginie PETRILLI, Centre de Recherche en Cancérologie de Lyon (representative of Inserm CSS) Mr Célio POUPONNOT, Institut Curie, Orsay Mr Ali TURHAN, Hôpital Paul Brousse, Villejuif
<b>HCERES scientific officer:</b>	Ms Urszula HIBNER

**Representatives of supervising institutions and bodies:**

Mr Vjekoslav DULIC, AP HP Hôpital Saint Louis

Mr Pierre GRESSENS, Faculté de Médecine

Ms Evelyne JOUVIN, Marche : ITMO I3M

Ms Laurence LOMME, Inserm DR7

Mr Mathieu RESCHE-RIGNON, Université Paris 7

Mr François SIGAUX, CEA

## INTRODUCTION

### HISTORY AND GEOGRAPHICAL LOCATION OF THE UNIT

The Inserm UMR-S 976 was created in 2009 at the historical Centre for Dermatology (Hôpital Saint Louis), by combining research and clinical teams under the direction of Mr Armand Bensussan and of Ms Martine Bagot acting as a deputy director. The unit was renewed in 2014 as a multi-thematic unit entitled "Onco-dermatology, Immunology and Cutaneous stem cells". The unit was devoted to basic and clinical research including reconstructive surgery and regenerative medicine in association with dermatology and dermatology and also some clinical activities (plastic surgery, burn unit).

The present project brings together 10 teams, of which 9 are already located on the St Louis site (albeit currently in different buildings) and one who will arrive from the Institut Curie.

The novel unit will be located at Saint Louis hospital, mainly at the "Institut Universitaire d'Hématologie" (IUH) and at the "Centre de Recherche sur la Peau" (CRP).

### MANAGEMENT TEAM

The unit's director is Mr Armand Bensussan with Mr Vassili Soumelis acting as deputy director. Mr Armand Bensussan will retire during the new mandate and Mr Vassili Soumelis will take over the direction of the unit.

### HCERES NOMENCLATURE

SVE1\_LS6 Immunologie, microbiologie, virologie, parasitologie.

SVE2\_LS3.

SVE1\_LS7.

### SCIENTIFIC DOMAIN

The primary objective of HIPI is to decipher novel immunological mechanisms at the molecular, cellular and tissue levels and its main strategy remains devoted to the development of a balanced basic and translational research as well as clinical oncology. This will be implemented in tight collaboration with Saint Louis Hospital clinical departments.

The new structure will focus on the following different scientific domains:

- *a- Immuno-oncology:* tumor micro-environment, cutaneous tumors including melanoma and NHL, breast and urological cancers, tumor genomics and immunity, oncogenic pathways and immunity and graft versus leukemias;
- *b- Stem cells and immunity:* hematopoietic stem cells, lymphoid development, cutaneous stem cells, mesenchymal stem cells and immunoregulation;
- *c- Immuno-inflammation:* inflammatory dermatoses, graft versus disease, transplantation, langerhans cell histiocytosis and allergy.

In addition to the 3 complementary fields, HIPI will also focus on the following cross-center projects (Technological/methodological transversal axes) that may contribute to the development of combined therapies through multi-disciplinary approaches including human cellular and tissue systems, bioinformatics, biostatistics, mathematical modeling and finally immunotherapy, immunomodulation, cell therapy.

## UNIT WORKFORCE

Unit workforce	Number 30/06/2017	Number 01/01/2019
<b>Permanent staff</b>		
Full professors and similar positions	26	34
Assistant professors and similar positions	12	13
Full time research directors (Directeurs de recherche) and similar positions	14	17
Full time research associates (Chargés de recherche) and similar positions	10	10
Other scientists ("Conservateurs, cadres scientifiques des EPIC, fondations, industries, etc.")	2	4
High school teachers	0	0
Supporting personnel (ITAs, BIATSSs and others, notably of EPICs)	22	31
<b>TOTAL permanent staff</b>	<b>86</b>	<b>109</b>
<b>Non-permanent staff</b>		
Non-permanent professors and associate professors, including emeritus	4	
Non-permanent full time scientists, including emeritus, post-docs	28	
Non-permanent supporting personnel	8	
PhD Students	34	
<b>TOTAL non-permanent staff</b>	<b>77</b>	
<b>TOTAL unit</b>	<b>159</b>	

## GLOBAL ASSESSMENT OF THE UNIT

In the period under evaluation (2012-2017), the teams of Inserm UMR-S 976 have made significant contributions in the field of immunodermatology, melanoma and regenerative medicine. Their high scientific quality is attested by over 500 publications, some of which are cutting-edge science published in high impact factor journals. Moreover, taking into account the incoming, teams, they have produced more than 1200 publications and contributed to more than 50 patents, licenced patents and inventions; 38 clinical trials, created 5 Biotech companies and have been involved in the development of some others. The unit is very competitive in fund raising at the national and international levels. The next contract will provide novel opportunities for strengthening interactions and synergies between the teams and optimising resources by sharing technological facilities. The solid continuum of research from basic science to clinical research and

practice is a clear asset. Globally, this is an excellent unit combining basic, translational and clinical research. The IHU technological platforms (imaging, functional genomic, data analysis) and the animal facility are used by the teams of the unit, and this clearly allows strengthening its translational research potential.



The evaluation reports of Hceres  
are available online: [www.hceres.com](http://www.hceres.com)

**Evaluation of clusters of higher education and research institutions**  
**Evaluation of higher education and research institutions**  
**Evaluation of research**  
**Evaluation of doctoral schools**  
**Evaluation of programmes**  
**International evaluation and accreditation**



2 rue Albert Einstein  
75013 Paris, France  
T. 33 (0)1 55 55 60 10

[hceres.com](http://hceres.com)

[@Hceres\\_](https://twitter.com/Hceres_)

[Hcéres](https://www.youtube.com/Hceres)

